Entries by gatekeeper

Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate

Synthetic vaccine designed to prime T-Cells to rapidly remove viral-infected cells from the body after infection May offer broad immunity against SARS-CoV-1 and all SARS-CoV-2 variants and provide long-lasting immunity that does not require seasonal booster vaccines Abingdon, Oxon, UK, 15 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling […]

Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants

The response to COVID-19 – a success story in vaccine development The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to […]

Nature paper provides further evidence of the benefits of eliciting a T-Cell response for COVID-19

Abingdon, Oxon, UK, 11 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines was pleased to read an interesting Nature paper published online yesterday, highlighting the role of T-Cells in some COVID-19 patients, providing rapid […]

Can One Vaccine Provide Immune Protection Against Multiple Pathogens?

Can One Vaccine Provide Immune Protection Against Multiple Pathogens? The idea of one vaccine offering a wide range of protection against multiple pathogens or strains is an attractive concept – it would reduce the demands on healthcare systems to deliver vaccination programmes, provide improved uptake of vaccines and reduce the burden for patients who may […]

T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why…

T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why… The human immune system has evolved over millennia and includes a multitude of different immune effector cells, antibodies and signalling molecules. As our knowledge of this complex system […]

Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine

Swiss regulatory authorities, including the Swiss Agency for Therapeutic Products (Swissmedic) have granted approval for a Phase I clinical trial of Emergex’s Dengue vaccine candidate The Phase I clinical trial will evaluate the safety and look for markers of T-Cell immune response in healthy volunteers Abingdon, Oxon, UK, 30 June 2021 – Emergex Vaccines Holding […]

Emergex Appoints Dr. Anthony Sedgwick as Non-Executive Director

Abingdon, Oxon, UK, 17 June 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, is pleased to announce that Dr. Anthony Sedgwick has been appointed to the Company’s Board as a Non-Executive […]

Emergex Strengthens Senior Management Team

Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director Abingdon, Oxon, UK, 23 February 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces […]

Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections

Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections U.S. federal appropriations reports encourage support for T-Cell vaccine approaches for pandemic influenza during the 2021 fiscal year Abingdon, Oxon, UK, 28 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease […]

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

  Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development […]